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ABSTRACT: Activation of seven-transmembrane (7TM)
receptors by agonists does not always lead to uniform
activation of all signaling pathways mediated by a given
receptor. Relative to other ligands, many agonists are “biased”
toward producing subsets of receptor behaviors. A hallmark of
such “functional selectivity” is cell type dependence; this poses
a particular problem for the profiling of agonists in whole cell
test systems removed from the therapeutic one(s). Such
response-specific cell-based variability makes it difficult to
guide medicinal chemistry efforts aimed at identifying and
optimizing therapeutically meaningful agonist bias. For this
reason, we present a scale, based on the Black and Leff
operational model, that contains the key elements required to describe 7TM agonism, namely, affinity (KA
−1) for the receptor
and efficacy (τ) in activating a particular signaling pathway. Utilizing a “transduction coefficient” term, log(τ/KA), this scale can
statistically evaluate selective agonist effects in a manner that can theoretically inform structure−activity studies and/or drug
candidate selection matrices. The bias of four chemokines for CCR5-mediated inositol phosphate production versus
internalization is quantified to illustrate the practical application of this method. The independence of this method with respect
to receptor density and the calculation of statistical estimates of confidence of differences are specifically discussed.
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It has long been acknowledged that the absolute potency of aseven-transmembrane (7TM) receptor agonist is as much
dependent on the properties of the biological assay system that
is utilized to determine agonist activity as it is on the molecular
properties of “affinity” and “intrinsic efficacy” that are operative
at the level of the target receptor itself.1,2 This is a major reason
why potency ratios between a group of agonists have been
traditionally preferred over absolute potencies when assessing
novel agonist structure−activity relationships (SAR); according
to classic receptor theory, agonist relative potency ratios should
be independent of the influence of receptor density and
stimulus−response coupling.3 In contrast to predictions of
classical receptor theory, however, response and cell-dependent
variations in agonist potency ratios have been increasingly
noted for more than 20 years.4−7 In fact, there is a large body of
compelling evidence that shows that not all agonists produce
uniform activation of 7TM receptors; this phenomenon,
commonly termed “functional selectivity” or “biased agonism”
(for reviews, see refs 8−14), causes ligands to have many
potential efficacies (“pluridimensional” efficacy15). One of the
main features of functional selectivity is variation in agonist
potency ratios with different cellular responses;16,17 this can
lead to problems in characterizing new agonist activity in test
systems for predictions of activity in other cell types (e.g.,
therapeutic systems).
An early discussion of functional selectivity, at that time
termed “stimulus trafficking”,18 proposed that the mechanism
underlying the phenomenon is one of agonist stabilization of
different receptor active state conformations, with the result
being that these unique conformations differentially activate
cellular signaling mechanisms in a manner that cannot be
explained simply by differences in stimulus−response coupling.
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This model leads to the conclusion that cytosolic signaling
molecules that directly interact with the active receptor
conformation are the discerning species linking the agonist
chemical structure with the observed phenotypic cellular
signaling profile. Under these circumstances, signaling mole-
cules can function as interrogating “probes” of the receptor
conformation. Thus, an ideal analytical approach for quantify-
ing agonist bias is one that incorporates elements of ligand
binding to the receptor and the ligand-bound receptor
subsequently binding to a signaling protein. These properties
are present in the “operational model” of Black and Leff,19
which explicitly describes agonist function in terms of two
hyperbolic processes, the ligand−receptor interaction and the
subsequent receptor−signal transduction cascade. A distinct
advantage of the model is that it can also be applied directly to
functional concentration−response data using routine non-
linear regression programs. Our study describes the application
of the Black−Leff operational model to furnish a quantitative
scale of agonist bias that may prove to be useful in facilitating
structure−activity relationships and optimization of agonist
phenotypic profiles. A key advantage of this method is that it
can furnish a stable internally consistent quantitative numerical
scale, amenable to statistical analysis, for chemists to gauge
ligand bias and functional selectivity. It is envisaged that the
determination of “bias factors” using this approach can also
contribute to the optimal design of drug candidate selection
matrices if biased agonism is a therapeutically desired outcome.
■ RESULTS AND DISCUSSION
Theoretical Model for Fitting Data. 7TM receptor
agonism can be defined as an allosteric system10 comprised
of a modulator (agonist), operating on a protein conduit
(receptor) to a protein guest (signaling molecule), as shown in
Figure 1. Cytosolic signaling proteins such as G proteins or β-
arrestin are known to affect the affinity of ligands for
receptors.17−20 Under these circumstances, receptor-mediated
cellular signaling changes caused by agonists must be described
both by affinity for the agonist and its efficacy. In the Black−
Leff operational model, the former property is quantified by the
agonist equilibrium dissociation constant (KA) whereas the
latter is determined by both the receptor density, [Rt], and the
parameter KE, which denotes the intensity of the reaction
(intrinsic efficacy of the agonist in activating a particular cellular
response pathway) and the ability of the system to convert a
receptor stimulus into a response. By taking the ratio [Rt]/KE,
we obtain a single parameter, denoted τ, that operationally
describes an agonist’s efficacy. The extension of this model to
the quantification of functional selectivity simply requires the
additional assumption that ligand bias is characterized by
different affinities and/or different intrinsic efficacies for
different receptor active states, i.e., different KA and/or different
KE (and, hence, τ) values.
The common form of the equation used for fitting the
Black−Leff operational model to concentration−response
curves of functional data describing receptor activation relates













where the maximal response of the system is given by Em, while
n is the “transducer slope” for the function linking agonist
concentration to measured response; this is not the same as the
Hill slope that is commonly used to describe the midpoint
gradient derived from logistic curve fitting of concentration−
response data, but the two parameters are related.20 In essence,
the Black−Leff model treats the agonist-bound receptor as a
“substrate”, the entire cell as a “virtual” enzyme, and the
parameters KA and KE (and τ) as the equilibrium constants
governing the “reaction”. The parameters Em and n are cell-
specific and thus shared by all agonists acting on a common
receptor through a given pathway, whereas KA is ligand
receptor-specific. The parameter τ is both ligand- and pathway-
specific. Therefore, any parameter that seeks to quantify
agonism in such an allosteric system should include both of
these latter two.
Fitting of functional data to eq 1 theoretically could
characterize agonism through some combination of KA and τ.
Accordingly, a parameter for characterizing agonism for any
given pathway defined by an agonist interacting with a receptor
(which interacts directly with a cytosolic signaling protein) can
be defined as a “transduction coefficient”, log(τ/KA) (see
Figure 1). The relative efficiency of agonists producing
activation of any pathway can thus be quantified with a
“normalized” transduction coefficient, namely Δlog(τ/KA).
This takes into account the natural bias of the system, in that
no two signaling pathways in the cell can be assumed to be
coupled to receptors with equal efficiency. Finally, to determine
the actual ligand “bias” of agonists for different signaling
pathways, it is necessary to statistically evaluate differences
between Δlog(τ/KA) values for a given agonist between the
pathways. The ligand bias [ΔΔlog(τ/KA) or log bias] for any
one pathway, j1, over another, j2, is given as
















Effect of Receptor Density on Log(τ/KA) Values. A
usable scale of agonism needs to be dependent only on the
intrinsic efficacy of the agonist (the component of KE unique to
Figure 1. Schematic diagram showing the relevance of the Black−Leff
operational model to quantification of agonist bias. The premise is
based on the fact that the receptor conformation stabilized by the
agonist will have a unique interaction with all signaling proteins that
directly interact with it, thereby setting up the allosteric system(s) of
modulator (agonist)/conduit (receptor)/guest (signaling protein).
Under these circumstances, the affinity and the efficacy (the “quality”
of the conformation) will be determined by the signaling protein, and
this will be unique for each pathway. The magnitude of log(τ/KA) will
be characteristic of both the affinity and efficacy of the agonist for a
particular pathway.
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the agonist chemical structure) and KA, and not dependent
upon receptor density and/or the tissue component of KE. In
this regard, it is worth comparing the log(τ/KA) scale to other
measures of agonist sensitivity in terms of the variation in
membrane receptor density.
The pEC50, i.e., the negative logarithm of the agonist
concentration producing the half-maximal response, is arguably
the most commonly used measure of agonist sensitivity. As
shown by Black et al.,20 the pEC50 of an agonist in terms of the















Another useful measure of agonist activity is Ehlert’s “activity
ratio” (denoted RA), which is given by the maximal response of
the agonist (Emax) divided by the EC50.
21−23 The log(RA) value
for an agonist in terms of the Black−Leff operational model is
given by
=






















Figure 2. Activity scales for agonists as a function of receptor density (e.g., different cell lines). Activities shown are log(τ/KA) (solid black line),
pEC50 (dotted line), and log(RA) (gray line) for different agonist concentration−response curve transducer slope coefficients. Curvature in these
relationships indicates variation in index with changes in receptor density as simulated by changes in τ, where τ = [Rt]/KE, with KE being constant.
Figure 3. Relative agonist activity as a function of changing receptor density. Values of log(τ/KA), pEC50, and log(RA) for two agonists (one
designated with a solid line and the other with a dotted line) were calculated for a range of τ values. (A) Because values of log(τ/KA) do not change
with receptor density, the ratio Δlog(τ/KA) remains constant over all ranges of receptor density. (B and C) The pEC50 values change with receptor
density for transducer slope coefficients of ≠1, leading to variance and reversal of ΔpEC50 values with receptor density (or changes in receptor
coupling efficiency, KE). (D and E) Values of log(RA) change with τ values for slope coefficients of ≠1, leading to differences in the value of
Δlog(RA) with varying receptor density as simulated by changes in τ.
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Figure 2 shows the effect of changing receptor density (as a
surrogate for comparing different tissues) on log(τ/KA), pEC50,
and log(RA) values. It can be seen that log(τ/KA) values are
linear with changing receptor density for any value of
transducer slope coefficient. In contrast, and as reported
previously by Ehlert,21 log(RA) is linear when n = 1 but not
when n ≠ 1; pEC50 values are nonlinear with changing receptor
density irrespective of the transducer slope. This becomes
important when these scales are used to compare two agonists.
It is imperative that a useful scale for quantifying agonism be
constant over a range of receptor densities because it would be
used to compare different cell types.
Figure 3 shows the behavior of log(τ/KA), pEC50, and
log(RA) for two agonists with changing receptor density at
different transducer slope coefficients. The key premise of this
paper is that the ratio of multiple indices of agonist activity [i.e.,
Δlog(τ/KA), ΔpEC50, or Δlog(RA)] needs to be constant over
a range of receptor densities to be of use in comparing relative
agonism in different tissues. As shown in Figure 3A, this is the
case for Δlog(τ/KA), where the distance between the lines for
the two agonists represents this ratio, and this remains constant
at any receptor density. It can be shown that when n = 1, RA
reduces to (τ/KA) (see eq 5); therefore; log(RA) also is
insensitive to differences in receptor density when n = 1. In
contrast, it can be seen that for transducer slope coefficients of
≠1, ΔpEC50 values (Figure 3B,C) and Δlog(RA) values
(Figure 3D,E) vary with changes in receptor density.
The possible dependence of Δlog(τ/KA) values with
changing receptor density was explored experimentally in a
recombinant CHO cell system whereby varying levels of CCR5
receptor density could be transduced through varying levels of
exposure to BacMam virus for the receptor.24 The concen-
tration−response curves for four chemokines in recombinant
CHO cell systems exposed to increasing levels of BacMam virus
for CCR5 expression are shown in Figure 4, and the resulting
log(τ/KA) values are listed in Table 1. The reference
chemokine agonist for these calculations was chosen to be
CCL3 (it should be noted that the actual agonist chosen as the
reference is immaterial with respect to the conclusions drawn
from the analysis). With CCL3 as the reference agonist, the
Δlog(τ/KA) values for the various levels of CCR5 expression
are also listed in Table 1. There was no statistically significant
difference between Δlog(τ/KA) values in the different systems,
in agreement with the predictions shown in Figure 3A, as
determined by the fact that no mean value exceeds the 95%
confidence interval of any other value.
The optimal test for the dependence on receptor number
would be calculation of log(τ/KA) over a wide range of receptor
densities; as seen in Table 1, baculovirus expression caused an
only 2−3-fold difference in log(τ/KA) values, indicating that an
only 2−3-fold difference in receptor expression was produced
by the procedure. To obtain a wider range of alterations of
receptor density, we performed additional studies on a different
system, namely the native muscarinic receptors expressed in
guinea pig ileum, where receptor density was manipulated
through irreversible alkylation of the muscarinic receptors by
the β-haloalkylamine phenoxybenzamine. Figure 5 shows
concentration−response curves for isotonic contraction of
guinea pig ileal smooth muscle through activation of muscarinic
receptors by carbachol or oxotremorine. It can be seen from the
figure that oxotremorine is 2-fold more potent as a full agonist
than carbachol in this assay. After a controlled alkylation of
muscarinic receptors through a 10 min exposure to 10 μM
phenoxybenzamine followed by a 2 h wash period, the
concentration−response curves for both agonists were
considerably shifted to the right with depressed maxima. In
accordance with the effects of decreasing system sensitivity on
high-affinity, low-efficacy agonists, the maximal response to
oxotremorine was depressed to a greater extent than that for
the higher-efficacy agonist carbachol. The Black−Leff model
Figure 4. Production of IP1 via activation of CCR5 receptors with CCL3L1 (gray filled circles), CCL5 (gray filled triangles), CCL3 (●), and CCL4
(□) in CHO cells expressing different levels of CCR5 as controlled by exposure to BaculoVirus concentrations. Data points represent means of three
experiments with curves fit to the operational model to mean data points.
Table 1. Log(τ/KA) and ΔLog(τ/KA) Values for Chemokine Agonists at Different Levels of CCR5 Receptor Transduction
mean log(τ/KA) value Δlog(τ/KA) valuea
10% baculovirus 5% baculovirus 1% baculovirus 10% baculovirus 5% baculovirus 1% baculovirus
CCL3L1 9.09, 9.28 to 8.9 9.14, 9.34 to 8.94 8.9, 9.15 to 0.34 0.62, 0.9 to 0.34 0.69, 0.9 to 0.34 0.73, 1.07 to 0.38
CCL5 9.0, 9.22 to 8.8 8.97, 9.16 to 8.77 8.7, 8.95 to 8.4 0.56, 0.84 to 0.28 0.52, 0.79 to 0.24 0.54, 0.89 to 0.2
CCL3 8.46, 8.66 to 8.27 8.45, 8.65 to 8.25 8.15, 8.4 to 7.9 0 0 0
CCL4 9.0, 9.2 to 8.8 8.8, 9.0 to 8.6 8.75, 9.0 to 8.5 0.55, 0.83 to 0.27 0.34, 0.64 to 0.04 0.6, 0.94 to 0.25
aThe reference agonist was CCL3.
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parameters describing these curves are listed in Table 2, where
it can be seen that the alkylation of receptors reduced the
system sensitivity by a factor of 152; i.e., the receptor number
was decreased to 0.6% of that of the control. The Δlog(τ/KA)
values changed very little from the control conditions to the
lower-sensitivity system (from 0.42 to 0.41), demonstrating the
stability of Δlog(τ/KA) values with the changing receptor
density.
IP1 versus CCR5 Internalization in U373 Cells:
Determination of Ligand Bias Factors. Concentration−
response curves for CCL3L1, CCL5, CCL3, and CCL4 were
obtained in U373-MAGI-CCR5-E cells for IP1 responses
(Figure 6A) and CCR5 internalization (Figure 6B); it can be
seen from these figures that the relative potencies of the
agonists differed considerably for these two CCR5-mediated
responses. As shown in Table 3, all four agonists were
essentially equiactive for the IP1 response pathway [as denoted
by the non-statistically significant differences in Δlog(τ/KA)]
but did differ in their ability to cause internalization. For this
pathway, CCL3L1, CCL5, and CCL4 are all statistically more
efficacious than CCL3 [see the Δlog(τ/KA) values in Table 3].
To determine the actual ligand bias of these agonists for
internalization versus the IP1 pathway, it is necessary to
statistically evaluate differences between Δlog(τ/KA) values for
each agonist between pathways, as calculated using eqs 2 and 3.
For these pathways in U373-MAGI-CCR5-E cells, ΔΔlog(τ/
KA) values for internalization versus IP1 indicate statistically
significant bias with CCL4, CCL5, and CCL3L1 toward
internalization by factors of 7.8, 21, and 23.7, respectively (see
Table 3). The statistical significance of these differences is
indicated by the 95% confidence limits of ΔΔlog(τ/KA) that do
not contain zero (the normalized value of the reference agonist,
CCL3). Figure 7 shows the graphical expression of Δlog(τ/KA)
and ΔΔlog(τ/KA) values and their 95% confidence intervals.
This gives a visual representation of statistical significance in
that if a mean value lies outside of the 95% confidence interval
of any other value, it is statistically significantly different from
that value. It can be seen from Figure 7 that for IP1, all agonists
are equivalent whereas for CCR5 internalization, CCL3L1,
CCL5, and CCL4 are more active in producing internalization
than CCL3 is. This translates into these three agonists also
being biased toward CCR5 internalization when compared to
IP1 production (see Figure 7).
It is also useful to view the ligand bias for these agonists in a
bias plot14,25 that expresses the response in one pathway as a
Figure 5. Guinea pig ileal smooth muscle contraction due to activation
of muscarinic receptors with carbachol (●) and oxotremorine (○).
Control curves show responses in normal tissue, and dashed curves are
curves in the same tissue after controlled alkylation of the muscarinic
receptor with 1 μM phenoxybenzamine (POB) for 10 min followed by
a 2 h drug free wash. Values in boxes refer to log(τ/KA) values for
control curves and curves after the reduction in receptor density. Data
points represent single curves in one tissue fit to the operational
model.
Table 2. Descriptors of Muscarinic Receptor Agonism in
Guinea Pig Ileum for Carbachol and Oxotremorinea
agonist τ pKa log(τ/KA) Δlog(τ/KA)
Control
carbarchol 1500 4.04 7.22 0.42
oxotremorine 120 5.56 7.64
After Alkylation
carbarchol 11 4.09 5.14 0.41
oxotremorine 0.71 5.69 5.55
aEm, the maximal response of the tissue, was obtained by measuring
the contraction of complete depolarization of guinea pig ileal strips to
KCl.
Figure 6. Concentration−response curves for chemokine activation of
the CCR5 receptor in U373 cells for production of IP1 (A) and
internalization of CCR5 (B). Curves shown for CCL3L1 (●), CCL5
(○), CCL3 (▲), and CCL4 (△). Data points represent the mean ±
standard error of the mean of five experiments for IP1 and three
experiments for internalization. Curves fitted through the points
represent the operational model.
Table 3. Data Describing Bias of Chemokine Agonists for




log(τ/KA) Δlog(τ/KA)a ΔΔlog(τ/KA) bias
IP1-U373
















CCL3 8.17, 8.49 to
7.84
0 0 1









CCL3L1 8.79, 9.2 to
8.36
1.58, 2.17 to 0.98
CCL5 8.53, 8.94 to
8.11
1.32, 1.9 to 0.73
CCL3 7.2, 7.6 to
6.79
0
CCL4 8.07, 8.49 to
7.65
0.86, 1.45 to 0.27
aThe reference agonist was CCL3.
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function of the response in the other pathway for equal
concentrations of agonist (see Figure 8). This plot incorporates
both system bias (it is unlikely that any two stimulus−response
pathways in any cell will be coupled with equal efficiency) and
any possible internal ligand bias. If the agonists are not
specifically uniquely biased for any one pathway, then all of the
ligands will produce a uniform line that would be skewed
positively or negatively (according to system bias) but showing
no differences between agonists. The curvature of the line
would simply reflect the relative coupling efficiency of the two
pathways in the cell for all agonists. However, if the curvature of
the lines differs for the agonists, this indicates that there are
intrinsic differences between the agonists for activation of the
two pathways; this is molecular bias that will be carried over to
all cells containing the receptor. As seen in Figure 8, there is
considerable between ligand bias for the agonists, with CCL3
being most biased toward IP1 and CCL3L1 the least. This
parallels the ΔΔlog(τ/KA) values of 1, 7, 21, and 23.7 for
CCL3, CCL4, CCL5, and CCL3L1, respectively (Table 3). It
should be noted that while bias plots in general are useful
graphical representations of selective agonism, they are
optimally effective when the bias is within a factor of 10−
100. A greater extreme of bias leads to highly skewed bias plots
that are limited in their ability to graphically show graded
response differences to agonists.
General Considerations in the Application of the Bias
Factor Approach. Descriptions of ligand bias are becoming
prevalent in pharmacological literature. As a preface to
discussions of how this phenomenon might be quantified, it
should be noted that all possible experimental factors that
might account for selective agonism, such as kinetics of
response, should be explored and ruled out as mechanisms of
selective agonism at one pathway over another. Once this is
done, methods can be applied to quantify ligand-based
stabilization of receptor active states and how those states
interact with cellular signaling pathways. It is envisaged that the
approach outlined above can provide a useful scale of agonism
that incorporates the minimal elements required to describe an
agonist’s activity, namely the normalized transduction coef-
ficient [Δlog(τ/KA)], which describes the relative efficiency of
agonist activity at a given pathway compared to a reference
agonist. Through this parameter, a second parameter, namely
the ΔΔlog(τ/KA) or log bias, that describes the bias that a
given agonist has between pathways relative to a reference
agonist can be obtained. This scale possesses the key properties
Figure 7. Graphical representations of mean values of Δlog(τ/KA) for IP1 production and CCR5 internalization with 95% confidence intervals.
These panels show that the potencies of these agonists are not statistically significantly different for IP1 production but that CCL3L1, CCL5, and
CCL4 are significantly more active for producing CCR5 internalization than CCL3. The right panel shows ΔΔlog(τ/KA) values that offset the effects
of system bias and compares the relative effects of the agonists on the two responses to a common reference agonist, namely CCL3. It can be seen
that CCL3L1, CCL5, and CCL4 are biased at the 95% confidence level for internalization vs IP1 production in U373 cells. Bars represent 95%
confidence intervals.
Figure 8. Bias plot for IP1 production (ordinates) and CCR5
internalization (abscissa) for chemokines in U373 cells. Curves
represent responses for the two respective pathways at equal
concentrations of agonist. The divergence in the curves represents
ligand bias based on receptor conformation that should be constant for
all systems.
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of being readily obtainable from operational model fitting of
experimental data {it should be noted that log[(Emax)/(EC50)],
an even more easily determined ratio, can be used as a
surrogate of log(τ/KA) for agonist dose−response curves with a
unit slope}, independent of variations in receptor density that
often occur between various cell types, amenable to statistical
evaluation, and internally consistent with no required
independent data acquisition (e.g., binding affinity data).
Theoretically, the log(τ/KA) scale is well suited for
quantification of the ability of agonists to stimulate a signaling
pathway. If functional selectivity of a given agonist is due to
selective activation of a pathway through separate coupling
proteins directly interacting with the active state receptor, then
the log(τ/KA) scale should detect the difference in efficacy and
affinity associated with the selectivity. This is because the
selective activation of the pathway should have associated with
it an affinity and efficacy of the receptor active state for the
coupling protein. It is essential for such a scale not to be
affected by differences in receptor density, as these are system
factors that often vary between cell types. As seen in Figure 3,
the pEC50 of an agonist changes with differences in receptor
density and thus is unsuitable as a scale for comparing cell
types. The activity ratio [log(RA)] is an equivalently suitable
scale if the transducer slope coefficient (and, hence, the Hill
slope) for the concentration response curves is unity but
becomes unstable at other values.
It is important to define the optimal conditions for using the
log(τ/KA) scale to quantify bias. The Black−Leff operational
model is suited to fit symmetrical and asymmetrical dose−
response curves. However, it should be noted that a reasonably
accurate estimate of Em, the maximal capability of the system to
produce response, is necessary for the correct estimation of KA
and τ. In practical terms, Em often can be estimated accurately
by observing the response to a known maximal stimulant (e.g.,
forskolin for cyclic AMP) or by observation of a common
maximal response to a number of agonists. In the latter case,
either all of the agonists would have to have identical efficacies
(unlikely) or the agonists saturate the stimulus−response
mechanism of the cell to produce full agonism equal to the
maximal response of the system (by definition Em). The
analysis with IP1 and CCR5 internalization also highlights
another feature of this approach, namely the statistical
estimation of bias. Given the right experiment, the use of a
pooled variance and the estimation of 95% confidence intervals
allows the independent assessment of differences in Δlog(τ/
KA) and ΔΔlog(τ/KA) values. Figure 9 shows a logical
progression for the analysis of ligand bias for two pathways
for a set of agonists with the associated statistical analysis.
Most 7TM receptors are pleiotropic in the sense that they
directly interact with more than one signaling protein (e.g.,
various G proteins, β-arrestin, etc.) in the cell.26−32 With this
comes the obligatory consideration of the relative efficiency
with which each pathway is coupled to the receptor. There is
no a priori reason to assume that all pathways will be uniformly
coupled to the receptor as this will be a function of the
equilibrium dissociation constant of the receptor and coupling
protein complex and the relative stoichiometry of the receptor
and coupling protein present in the cell. Thus, cells can
effectively emphasize the importance of relative pathways
through control of the relative stoichiometries of these
components. If the agonists produce the same receptor active
conformation to trigger the effect, then all agonists will be
subject to this system bias and no between cell differences in
agonist effect will be seen. The calculation of Δlog(τ/KA)
values accounts for the system bias by relating agonism to a
reference agonist; i.e., the Δlog(τ/KA) scale relates the agonists
to each other in terms of power to elicit activation of a
particular pathway with all of the effects subjected equally to
system bias. However, once this has been done, then Δlog(τ/
KA) values should be constant between cell types if the agonists
produce the same active state receptor, because there would
only be a phase change in amplification of the signals with no
between agonist differences. If differences in Δlog(τ/KA) values
are seen between pathways [as measured by ΔΔlog(τ/KA)
values], then this suggests that the agonists discern the
pathways differently; i.e., they produce active receptor
conformations different from each other. Under these circum-
stances, the ΔΔlog(τ/KA) scale defines true ligand bias that is
unique to the receptor−agonist pair. Therefore, if biased
agonism is a desired profile, the ΔΔlog(τ/KA) scale can be used
by medicinal chemists to optimize the effect.
The fact that agonists can produce cell-specific signaling
profiles offers unique therapeutic opportunities. However, the
very property of such agonists that may be of utility is also the
property that is most difficult to quantify and predict because it
may vary with cell type. Given that the prevalence of functional
selectivity in the actions of 7TM ligands is markedly on the rise
in both academic and industrial settings, the availability of such
a robust scale should provide a valuable tool for facilitating the
dialogue between medicinal chemistry and biology targeted
toward novel 7TM receptor drug discovery and structure−
activity studies. As whole cell response assays become
increasingly common, for example, with label free technology,
it would be predicted that variances in agonist relative potency
(relative efficacy) will be observed; these effects have been
reported in the literature,17 and in fact, variance in cell-based
agonist activity has been described as a method for detecting
functional selectivity.16 This raises the specter of cell-based
Figure 9. Schematic diagram showing the logistical progression for
analysis of agonist bias using the Black−Leff operational model with a
statistical assessment of selectivity.
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efficacy (as defined by Stephenson1) becoming obsolete as a
quantitative scale for predictive pharmacology. However, the
concept of efficacy is clearly required thermodynamically,
because a ligand-bound receptor necessarily is different (i.e.,
“isomerized”33) from an unliganded one; this is what
Furchgott2 termed intrinsic efficacy. Therefore, what is needed
is a way to access intrinsic efficacy in cell-based systems so that
it may function as a cell-type-independent scale for quantifying
agonism. Proposed here is the idea that a pathway efficacy,
directly emanating from a physical interaction of the receptor
conformation with a cytosolic signaling molecule, may function
as a surrogate of intrinsic efficacy. The intent of such a scale is
to provide medicinal chemists with a way to quantify bias in any
given molecule and thus constructively optimize it if required.
The ability of the ΔΔlog(τ/KA) bias scale to detect
functional selectivity depends on the interaction of system
bias and ligand bias; i.e., true ligand bias will be most evident if
extremes in signaling can be assayed. For the chemokine data
shown in our study, this was accomplished through measure-
ment of extremes linked to actual binding partners of the
receptor, in this case G protein and β-arrestin. Interestingly, the
β-arrestin (internalization) bias for CCL3L1 may be therapeuti-
cally significant in light of data linking the gene copy number
for CCL3L1 in HIV-infected patients to survival with AIDS.34
Our analysis indicates that CCL3L1 is statistically biased
toward inducing CCR5 receptor internalization; cell surface
CCR5 has been linked to predilection toward HIV infection
and progression to AIDS, and it has been found that high levels
of CCL3L1 are linked with lower cell surface levels of CCR5.35
It would be envisioned that for the total cell response in two
cell types (i.e., pERK activation due to activation of G proteins
and β-arrestin36), the ligand bias would not be as obvious; i.e.,
while one cell type may be more reliant on β-arrestin signaling
than another, there would be more of a mixture of effect and
true ligand bias would be more subtle and difficult to quantify.
However, this could also yield a strategy for the discovery of
new functionally selective agonists. Specifically, if two agonists
produce cell-specific potency ratios, this would furnish
presumptive evidence that they produce different receptor
active states; i.e., they are functionally selective.16
In summary, biased agonism is a frequently encountered
phenomenon, and we cannot assume that new synthetic
agonists activate receptors in a manner identical to that of the
natural hormone. Insofar as functional activity controls the
cellular phenotypic agonism, it is important both to recognize if
an agonist is biased and to associate functional bias with clinical
phenotype. In this latter instance, it would be predicted that
defined bias has the potential to create more selective
agonists;11 in this regard, the log(τ/KA) scale may be a useful
tool for guiding medicinal chemistry.
■ METHODS
Cell Culture. Stable U373-MAGI-CCR5-E cells were generated by
M. Emerman and obtained through the NIH AIDS Research and
Reagent Program (catalog no. 3597). The cells were carried in
continuous culture in T225 tissue culture flasks (NUNC, catalog no.
159934) in growth medium containing DMEM/F12 (Gibco, catalog
no. 11039) with 10% fetal bovine serum (Gibco, catalog no. 26140)
and 1% Glutamax (Gibco, catalog no. 35050061). Cells were not
allowed to become confluent and were ∼85% confluent at the time
they were harvested for the assay. Transient CCR5-expressing CHO
CGE cells were generated as follows. Frozen vials of CHO CGE cells
were quickly thawed and resuspended in medium containing DMEM/
F12 (Gibco, catalog no. 11039) with 10% fetal bovine serum (Gibco,
catalog no. 26140) and 1% Glutamax (Gibco, catalog no. 35050061).
The cell suspension was centrifuged at 1000g for 5 min to pellet cells.
After centrifugation, the cell pellet was resuspended in fresh DMEM/
F12 medium at a density of 106 cells/mL. Transduction preps were
prepared by addition of the CCR5 bacmam virus at 1, 5, or 10% (v/v)
along with 107 cells and qs volume to 40 mL with growth medium.
These preps were put into T225 culture flasks (NUNC, catalog no.
159934) and placed in a humidified 37 °C incubator for 24 h prior to
the assay.
IP1 Accumulation Assay. U373-MAGI-CCR5-E cells were cultured
as described above and were ∼85% confluent at the time they were
harvested. On the day of the assay, cells were washed once with 10 mL
of PBS, and then 3 mL of the cell dissociation solution was added to
each flask. The flasks were incubated for 5 min at 37 °C to facilitate
cell removal. After incubation, each flask was washed with 10 mL of
growth medium, and cells were collected in a 50 mL conical tube. The
cell suspension was counted in a Beckman Coulter Z1 cell counter and
then centrifuged to pellet cells (800g for 5 min).
After centrifugation, cells were resuspended in the stimulation
buffer provided in the IPOne kit at a density of 2.86 × 106 cells/mL.
Using a Multidrop Combi (Thermo Scientific), 7 μL of the cell
suspension per well was added to the plate containing chemokines
(final density of 20000 cells/well). A dark lid was placed on the plates,
and they were incubated for 60 min at 37 °C.
Once the 60 min incubation was complete, we added 3 μL of IP1-
d2 and then 3 μL of the anti-IP1-cryptate solutions provided in the
IPOne kit using a Multidrop Combi. The plates were shaken for 1 min
to ensure reagents were mixed. Plates were covered and incubated for
60 min at room temperature. After being incubated, the plates were
read on a PE Viewlux instrument and the data expressed as the
10000(acceptor counts/donor counts) ratio.
Guinea Pig Ileum Contraction. Proximal ileum from guinea pigs
(sacrificed by cervical dislocation) was removed and placed in a
Tyrode solution (167 mM Na+, 2.67 mM K+, 1.8 mM Ca2+, 1.0 mM
Mg2+, 145 mM Cl−, 29.7 mM H2CO3
−, 0.36 mM H2PO4
2−, and 22 mM
D-glucose). The contents of the ileum were flushed with a Tyrode
solution, and the ileum was drawn over a glass rod. The external
longitudinal muscle layer was cut through with a scalpel and the
muscle gently removed through teasing with a cotton swab.37 The
resulting strip of longitudinal smooth muscle was mounted in a heated
(37 °C) organ bath filled with an oxygenated (95% O2/5% CO2)
Tyrode solution. One end of the muscle was fixed to the organ bath
while the other tied to a Hewlett-Packard linear motion isotonic
transducer (model 1000-7DCDT) under a resting tension of 400 mg.
The Tyrode solution was removed and replaced with a fresh solution
every 20 min while the preparation was left to equilibrate for 60 min.
Cumulative concentration−response curves to carbachol and
oxotremorine (isotonic contraction) were recorded on a Grass
model 5P1 polygraph recorder. After equilibration with a drug free
Tyrode solution for a further 60 min, tissues were subjected to a
controlled chemical alkylation via the addition of 1 μM phenoxybenz-
amine for 10 min followed by washing with a drug free Tyrode
solution. Tissues were washed every 20 min for 2 h with the first three
reapplications of Tyrode containing 1.0 mM sodium thiosulfate to
remove unreacted aziridinium ion.38 After a total wash time of of 2 h,
concentration−response curves for carbachol and oxotremorine were
obtained in the chemically treated tissues.
Internalization of CCR5. U373-MAGI-CCR5-E cells were plated in
PE 96-well View plates and harvested from the culture flask using cell
dissociation solution from Sigma (catalog no. C5914, 100 mL). The
plates were then plated at a density of 17000 cells/well in 96-well View
plates from Perkin-Elmer (catalog no. 6005182) and incubated for
≈15 h at 37 °C and 5% CO2.
Cells were then washed twice with 50 μL of PBS (pH 7.2) per well.
Test compounds were prepared as 1:5 serial dilutions in a 100:1
DMSO solution and then diluted to a 1:100 ratio in MEM-alpha and
1% FCS. Cells were incubated with 100 μL of test compound for 35
min at 37 °C and 5% CO2, washed twice with PBS, fixed with 3.7%
paraformaldehyde, and incubated at room temperature inside a
chemical hood for 30 min. The cells were then washed twice with
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50 μL of wash buffer [0.5% Tween 20 in PBS buffer (pH 7.2)] per
well. Cell membranes were stained with 4 ng/mL [PBS (pH 7.4)]
wheat germ agglutinin-Alexa 488 from Molecular Probes (catalog no.
W11261) for 30 min in the dark. The cells were then washed twice
with 50 μL of wash buffer per well, and 50 μL of 3.7%
paraformaldehyde per well was added. This mixture was incubated
for 5 min in a chemical hood. The cells were then washed twice with
50 μL of wash buffer per well prior to being blocked with 50 μL of 1%
BSA and 1% normal goat serum (Sigma, catalog no. 15256, 50 mg) in
PBS (pH 7.2) for 30 min and then permeabilized with PBS (pH 7.2)
and 0.2% Triton-X (Sigma, catalog no. T8787) for 15 min in the dark.
The CTC8 (R&D MAB1801) mouse anti-human CCR5 primary
antibody was reconstituted in PBS (pH 7.2) and 0.5% BSA to a final
concentration of 500 μg/mL. The primary antibody solution was
prepared by mixing block buffer with CTC8 to a final concentration of
3 μg/mL. The permeabilization buffer from the previous step was
aspirated and 50 μL of primary antibody solution per well added.
Plates were then incubated at room temperature (in the dark) for 40
min. After the incubation, cells were washed twice with 50 μL of wash
buffer per well; 50 μL of secondary goat anti-mouse Alexa-568 F (AB′)
from Molecular Probes (catalog no. A11019), 6 μg/mL in 2 μM
Hoeschst 33342 (Lonza Walkersville Inc., catalog no. PA-3014), in
blocking buffers was added and the plate incubated at room
temperature and protected from light for 40 min. After the incubation,
the cells were washed three times with 50−100 μL of wash buffer per
well and then stored in 100 μL of PBS buffer (pH 7.2) per well. The
plates were sealed with Top Seal-A (catalog no. 6005185, Perkin-
Elmer) and the bottoms of the plates wiped with 70% ethanol to
remove any possible water marks. The plates were read using the
Cellomics Array Scan II Instrument; data were analyzed with the
GPCR Bioapplication algorithm.
Compound Preparation. All chemokines tested were purchased
from Peprotech (Rock Hill, NJ). Chemokines were diluted in
deionized water to a stock concentration of 100 μM, aliquoted, and
kept frozen at 20 °C. On the day of the assay, the chemokines were
serially diluted at 2 times the final assay concentration in stimulation
buffer provided in the IPOne HTRF assay kit (Cisbio). Finally, 7 μL of
the 2× sample for the chemokine concentration−response curves was
added to the assay plate (NUNC, catalog no. 167462).
Data Analysis. The determination of Δlog(τ/KA) values and their
use in determining ligand bias are shown schematically in Figure 9.
Agonist concentration−response curves are fitted to the Black−Leff
operational model to determine values of τ and KA (box 1, Figure 9;
see also Appendix 1: Fitting the Black−Leff Model). For each
concentration−response curve, a value for the transduction coefficient
[log(τ/KA)] is calculated; this is a parameter that summarizes the
power of the agonist to activate the particular stimulus−response
mechanism that is being measured by the assay. Individual estimates of
these transduction coefficients are then used to calculate a mean value
(summarizing repeat estimates for the agonist in the system), and a
value of variance also is calculated (box 2, Figure 9). These variances
can then be combined for all of the agonists in all of the assays to yield
an estimate of the pooled variance (box 3, Figure 9), which then can
be used to calculate the 95% confidence intervals of the various
transduction coefficients of the agonists for the pathway (box 4, Figure
9).
It is important to choose a reference agonist at this point to cancel
the effects of system bias on subsequent estimation of ligand bias. If
this were not done, then comparison of any agonist across two
response pathways would show a bias due to the fact that the two
different assays simply are of differing sensitivity. Comparison to an
internal standard within each assay (it must be the same one for both
pathway responses) cancels differences in coupling sensitivity and
efficiency of transduction of the two pathways because they are then
common to all the agonists (box 5, Figure 9). Therefore, Δlog(τ/KA)
values are calculated along with 95% confidence intervals of these
estimates (box 6, Figure 9). At this point, the agonists can be
compared within a pathway to determine differences in their ability to
activate the pathway. If the value of zero lies within any 95%
confidence interval for any agonist, this indicates the agonist is not
significantly different from the reference agonist as an activator of the
pathway.
This procedure serves to characterize the relative ability of a group
of agonists to activate a given pathway. Steps 1−6 are then repeated
for the agonists with another assay measuring response to the pathway
to be compared (box 7, Figure 9). The two sets of Δlog(τ/KA) values
then are subtracted to yield ΔΔlog(τ/KA) values (box 8, Figure 9),
which indicate the relative activity of the agonists on each pathway
corrected for system bias through comparison to a common reference
agonist. The 95% confidence intervals of these ΔΔlog(τ/KA) values
(bias parameters) are also calculated (box 9, Figure 9). As with
Δlog(τ/KA) values, if zero lies within the 95% confidence interval of a
ΔΔlog(τ/KA) estimate, this indicates that the agonist is equiactive in
the two pathways. However, if this is not the case, it indicates that the
agonist is biased at the molecular level for one pathway over the other.
■ APPENDIX 1: FITTING THE BLACK−LEFF MODEL
The Black−Leff operational model (1983) is the standard
model for fitting concentration−response curves of functional
data describing receptor activation. The equation for this model













where the maximal response of the system is given by Em, n is a
fitting parameter for the slope, the affinity of the agonist is
represented by the equilibrium dissociation constant of the
agonist−receptor complex, KA, and the efficacy of the agonist is
defined by τ.
When the four-parameter Black−Leff model is being fit with
ordinary least-squares methods, the model appears to be nearly
unidentifiable. This statistics term means that two sets of
parameters can yield the same responses for all values of [A].
For example, the two parameter sets, (Em = 100, KA = 10
−6, τ =
0.1, n = 3) and (Em = 104, KA = 10
−6, τ = 0.0215, n = 3),
produce nearly identical curves. As discussed, the parameter of
interest in the main text is log(τ/KA). For the two parameter
sets that produce nearly identical curves, the values for log(τ/
KA) are 5.0 and 4.3, respectively. To ameliorate this problem, it
is our recommendation that the parameter Em be held fixed.
This suggests that the investigator will likely need to run a
separate study to determine a precise estimate of Em. Our
simulation studies show that when Em is held fixed, the
distribution for estimated log(τ/KA) values is symmetric (and,
hence, the mean is unbiased for the central value). In contrast,
when all four model parameters are estimated (including Em),
the distributions for the estimates of log(τ/KA) are skewed (so
that the mean is no longer the central value) and are often too
variable to be of any use. For example, when Em = 1, KA = 10
−7,
τ = 15, and n = 0.7, the standard deviations of the estimates for
log(τ/KA) were nearly 6 times larger when estimating Em versus
when Em (1.0) was held fixed.
A useful reparametrization of eq A1 that we found to be
stable for ordinary least-squares curve fitting is
=
















where β1 = ln(KA) and β2 = ln(τ). Then the parameter of
interest is log10(τ/KA) = (β2 − β1)/ln(10).
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■ APPENDIX A2: ESTIMATING BIAS
A straightforward experimental and analytical approach to
estimating bias is given in this section. Suppose that serial
dilutions for K ≥ 2 agonists (for the Black−Leff dose−response
curve) are laid out on N1 plates with their signal measured for
pathway 1 via some assay. Further suppose the same process is
repeated on N2 plates to measure the signal for pathway 2 via a
second assay.
For each plate, pathway, and agonist, fit the Black−Leff
model using eq A2 to estimate log(τ/KA). One can model the
system with a one-way analysis of variance (ANOVA) model as
follows
= θ + εYijk ij ijk (A3)
where Yijk values are the estimated log(τ/KA) values, θij values
are the mean parameter values, and εijk values are the model
errors for agonist i = 1, 2, ..., K; pathway j = 1 or 2; and plate k
= 1, 2, ..., Nj. The εijk values are typically assumed to be
independent and to be identical distribution normal random
variables with a zero mean and a standard deviation σ. In case
the samples are not completely balanced, let Nij denote the
total number of observations for agonist i and pathway j.
Given the model assumptions in eq A3, the following text
shows how to estimate the mean, the standard error, and a 95%

































denote the sample mean and sample variance for the log(τ/KA)
value for agonist i and pathway j, respectively. An estimate for





































Let Δlog(τ/KA) denote the difference in log(τ/KA) values for
agonists i and i′. This parameter is estimated by Y̅ij − Y̅i′j, with









Bias, denoted by ΔΔlog(τ/KA), is the difference in Δlog(τ/KA)
for the two pathways and is estimated by (Y̅i1 − Y̅i′1) − (Y̅i2 −
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A 95% confidence interval for any of these parameters [log(τ/
KA), Δlog(τ/KA), or ΔΔlog(τ/KA)] is
± T f(estimate) (d , 0.975)(standard error)error (A9)
where T(λ,p) is the upper pth quantile of the central T
distribution with λ degrees of freedom. For example, a 95%
confidence interval for bias is given by
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The steps described above represent one way to design a
study to determine bias, but it should be recognized that special
features of the experiment could warrant modifications of the
design. If, for example, there appears to be a significant plate
effect, one could add a plate term to eq A3 and instead use the
model Yijk = Pk + θij + εijk, where Pk is the term for plate k. A
second deviation of eq A3 may be necessary if the assumption
of a constant standard deviation is ignored. That is, if the
standard deviation does not appear to be approximately the
same within all agonist and pathway groups, then the pooled
standard deviation estimate cannot be used, and one would
need a more complicated approach (e.g., Satterthwaite
approximation to degrees of freedom). Finally, the researcher
may wish to deviate from the simple experimental plan outlined
above. The statistical model fit to the data should accurately
reflect the experiment that was conducted.
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